Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference
Quanterix (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Masoud Toloue and CFO Vandana Sriram will engage in a fireside chat on September 6, 2024, at 1:50 p.m. ET.
The presentation will be accessible virtually, with registration available online. Following the conference, the presentation will be viewable on Quanterix's website in the investor relations section. This event provides an opportunity for investors and stakeholders to gain insights into Quanterix's innovative Simoa® technology and its role in advancing scientific discovery through precise biomarker detection.
Quanterix (NASDAQ: QTRX), un leader nella rilevazione ultrasensibile dei biomarker, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale sulla Sanità Globale di Morgan Stanley. Il CEO Masoud Toloue e il CFO Vandana Sriram parteciperanno a un colloquio informale il 6 settembre 2024, alle 13:50 ET.
La presentazione sarà accessibile virtualmente, con registrazione disponibile online. Dopo la conferenza, la presentazione sarà visibile sul sito web di Quanterix nella sezione delle relazioni con gli investitori. Questo evento offre un'opportunità per investitori e stakeholders di ottenere informazioni sulla tecnologia Simoa® di Quanterix e sul suo ruolo nell'avanzamento della scoperta scientifica attraverso la precisa rilevazione dei biomarker.
Quanterix (NASDAQ: QTRX), un líder en la detección ultrasensible de biomarcadores, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El CEO Masoud Toloue y la CFO Vandana Sriram participarán en una charla informal el 6 de septiembre de 2024, a la 1:50 p.m. ET.
La presentación será accesible de forma virtual, con registro disponible en línea. Después de la conferencia, la presentación se podrá ver en el sitio web de Quanterix en la sección de relaciones con inversores. Este evento ofrece una oportunidad para que inversores y partes interesadas obtengan información sobre la tecnología Simoa® de Quanterix y su papel en el avance del descubrimiento científico a través de la precisa detección de biomarcadores.
Quanterix (NASDAQ: QTRX), 초민감 바이오마커 탐지의 선두주자가, 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO 마수드 톨루에와 CFO 반다나 스리람이 2024년 9월 6일 오후 1시 50분 ET에 파이어사이드 채팅에 참여합니다.
프레젠테이션은 온라인으로 등록할 수 있으며 가상으로 접근 가능하게 됩니다. 컨퍼런스 이후에는 Quanterix 웹사이트의 투자자 관계 섹션에서 프레젠테이션을 볼 수 있습니다. 이 이벤트는 투자자와 이해관계자에게 Quanterix의 혁신적인 Simoa® 기술 및 정밀한 바이오마커 탐지를 통한 과학적 발견의 발전에 대한 통찰을 제공할 기회를 제공합니다.
Quanterix (NASDAQ: QTRX), un leader dans la détection ultrasensible des biomarqueurs, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Le PDG Masoud Toloue et le CFO Vandana Sriram participeront à une discussion informelle le 6 septembre 2024 à 13h50 ET.
La présentation sera accessible virtuellement, avec une inscription disponible en ligne. Après la conférence, la présentation sera visible sur le site web de Quanterix dans la section des relations investisseurs. Cet événement offre une occasion aux investisseurs et aux parties prenantes d'obtenir des informations sur la technologie Simoa® de Quanterix et son rôle dans l'avancement de la découverte scientifique grâce à la détection précise des biomarqueurs.
Quanterix (NASDAQ: QTRX), ein führendes Unternehmen in der ultrasensiblen Biomarkerdetektion, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley angekündigt. CEO Masoud Toloue und CFO Vandana Sriram werden am 6. September 2024 um 13:50 Uhr ET an einem Fireside Chat teilnehmen.
Die Präsentation wird virtuell zur Verfügung stehen, mit einer Online-Registrierung. Nach der Konferenz wird die Präsentation auf der Website von Quanterix im Bereich Investor Relations verfügbar sein. Diese Veranstaltung bietet eine Gelegenheit für Investoren und Interessierte, Einblicke in die innovative Simoa®-Technologie von Quanterix und deren Rolle bei der Förderung wissenschaftlicher Entdeckungen durch präzise Biomarkerdetektion zu erhalten.
- None.
- None.
To learn more about Quanterix, visit www.quanterix.com/company/. To learn more about Quanterix’s Simoa® technology, visit: www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829576786/en/
Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations Contact:
Francis Pruell
(508) 789-1725
ir@quanterix.com
Source: Quanterix Corporation
FAQ
When is Quanterix (QTRX) participating in the Morgan Stanley Healthcare Conference?
Who will represent Quanterix (QTRX) at the Morgan Stanley Healthcare Conference?
How can I access Quanterix's (QTRX) presentation at the Morgan Stanley Healthcare Conference?
What is Quanterix's (QTRX) main focus in biomarker detection?
